Strata Critical Medical (NASDAQ:SRTA) CEO William Heyburn Sells 31,671 Shares

Strata Critical Medical (NASDAQ:SRTA) CEO William Heyburn sold 31,671 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.87, for a total value of $185,908.77. Following the completion of the sale, the chief executive officer owned 1,548,997 shares of the company’s stock, valued at approximately $9,092,612.39. The trade was a 2.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Strata Critical Medical Stock Performance

Shares of SRTA opened at $5.48 on Thursday. The stock has a 50-day moving average of $5.17. The stock has a market capitalization of $474.18 million, a PE ratio of -68.50 and a beta of 2.20. Strata Critical Medical has a 52 week low of $3.57 and a 52 week high of $6.50.

Strata Critical Medical (NASDAQ:SRTA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.07. The business had revenue of $67.38 million during the quarter. Strata Critical Medical had a negative return on equity of 4.06% and a net margin of 20.56%. Equities research analysts forecast that Strata Critical Medical will post -0.14 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on SRTA shares. Craig Hallum started coverage on Strata Critical Medical in a research report on Wednesday, March 25th. They set a “buy” rating and a $8.00 target price for the company. Zacks Research upgraded Strata Critical Medical to a “hold” rating in a research report on Thursday, March 26th. B. Riley Financial started coverage on Strata Critical Medical in a research report on Wednesday, March 25th. They set a “buy” rating and a $8.00 target price for the company. Finally, Weiss Ratings upgraded Strata Critical Medical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Hedge Funds Weigh In On Strata Critical Medical

Several institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its holdings in Strata Critical Medical by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,617,104 shares of the company’s stock valued at $6,759,000 after buying an additional 172,154 shares in the last quarter. Bank of America Corp DE grew its holdings in Strata Critical Medical by 16.2% during the 1st quarter. Bank of America Corp DE now owns 181,574 shares of the company’s stock valued at $759,000 after buying an additional 25,379 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Strata Critical Medical by 98.7% during the 1st quarter. Quantinno Capital Management LP now owns 143,239 shares of the company’s stock valued at $599,000 after buying an additional 71,155 shares in the last quarter. Principal Financial Group Inc. purchased a new position in Strata Critical Medical during the 1st quarter valued at approximately $537,000. Finally, Seelaus Asset Management LLC grew its holdings in Strata Critical Medical by 32.7% during the 1st quarter. Seelaus Asset Management LLC now owns 24,350 shares of the company’s stock valued at $102,000 after buying an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 47.36% of the company’s stock.

Strata Critical Medical Company Profile

Blade Air Mobility, Inc provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.